featured
Durable Molecular Remissions in CLL Treated With CD19-Specific CAR T Cells After Failure of Ibrutinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
J. Clin. Oncol 2017 Jul 17;[EPub Ahead of Print], CJ Turtle, KA Hay, LA Hanafi, D Li, S Cherian, X Chen, B Wood, A Lozanski, JC Byrd, S Heimfeld, SR Riddell, DG MaloneyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.